[go: up one dir, main page]

MX2009010761A - Formas cristalinas de 6-[2-(metilcarbamoil)fenilsulfanil]-3-e-[2-( piridin-2-il)etenil]indzol adecuadas para el tratamiento del crecimiento celular anormal en mamiferos. - Google Patents

Formas cristalinas de 6-[2-(metilcarbamoil)fenilsulfanil]-3-e-[2-( piridin-2-il)etenil]indzol adecuadas para el tratamiento del crecimiento celular anormal en mamiferos.

Info

Publication number
MX2009010761A
MX2009010761A MX2009010761A MX2009010761A MX2009010761A MX 2009010761 A MX2009010761 A MX 2009010761A MX 2009010761 A MX2009010761 A MX 2009010761A MX 2009010761 A MX2009010761 A MX 2009010761A MX 2009010761 A MX2009010761 A MX 2009010761A
Authority
MX
Mexico
Prior art keywords
phenylsulfanyl
methylcarbamoyl
indazole
ethenyl
pyridin
Prior art date
Application number
MX2009010761A
Other languages
English (en)
Inventor
Anthony Michael Campeta
Brian Patrick Chekal
Robert William Mclaughlin
Robert Alan Singer
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39831473&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2009010761(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MX2009010761A publication Critical patent/MX2009010761A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a formas polimórficas y amorfas cristalinas de 6-[2-(metilcarbamoil)fenilsulfanil]-3-E-[2-(piridin -2-il)etenil]indazol y a métodos para su preparación; la invención también se dirige a composiciones farmacéuticas que contienen al menos una forma polimórfica y al uso terapéutico o profiláctico de tales formas y composiciones polimórficas.
MX2009010761A 2007-04-05 2008-03-25 Formas cristalinas de 6-[2-(metilcarbamoil)fenilsulfanil]-3-e-[2-( piridin-2-il)etenil]indzol adecuadas para el tratamiento del crecimiento celular anormal en mamiferos. MX2009010761A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US91037907P 2007-04-05 2007-04-05
US97654607P 2007-10-01 2007-10-01
US3155408P 2008-02-26 2008-02-26
PCT/IB2008/000792 WO2008122858A2 (en) 2007-04-05 2008-03-25 Crystalline forms of 6- [2- (methylcarbamoyl) phenylsulfanyl] -3-e- [2- (pyridin-2-yl) ethenyl] indazole suitable for the treatment of abnormal cell growth in mammals

Publications (1)

Publication Number Publication Date
MX2009010761A true MX2009010761A (es) 2009-10-28

Family

ID=39831473

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009010761A MX2009010761A (es) 2007-04-05 2008-03-25 Formas cristalinas de 6-[2-(metilcarbamoil)fenilsulfanil]-3-e-[2-( piridin-2-il)etenil]indzol adecuadas para el tratamiento del crecimiento celular anormal en mamiferos.

Country Status (23)

Country Link
US (1) US8791140B2 (es)
EP (4) EP4249063A3 (es)
JP (2) JP5869197B2 (es)
KR (1) KR101237588B1 (es)
CN (2) CN103626739B (es)
AR (1) AR065931A1 (es)
AU (1) AU2008236444B2 (es)
BR (1) BRPI0809471A2 (es)
CA (1) CA2682859C (es)
CY (1) CY1119119T1 (es)
DK (1) DK2134702T4 (es)
ES (2) ES2919351T3 (es)
FI (1) FI2134702T4 (es)
IL (1) IL201320A (es)
MX (1) MX2009010761A (es)
NZ (1) NZ580126A (es)
PL (1) PL2134702T5 (es)
PT (1) PT2134702T (es)
RU (1) RU2518898C2 (es)
SG (1) SG156088A1 (es)
SI (1) SI2134702T2 (es)
TW (1) TWI481602B (es)
WO (1) WO2008122858A2 (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2134702T (pt) 2007-04-05 2017-07-31 Pfizer Prod Inc Formas cristalinas de 6-[2-(metilcarbamoil)fenilsulfanil]-3-e-[2-(piridin-2-il)etenil]indazol adequadas para o tratamento de crescimento celular anormal em mamíferos
WO2012042421A1 (en) 2010-09-29 2012-04-05 Pfizer Inc. Method of treating abnormal cell growth
JO3062B1 (ar) * 2010-10-05 2017-03-15 Lilly Co Eli R)-(e)-2-(4-(2-(5-(1-(3، 5-داي كلورو بيريدين-4-يل)إيثوكسي)-1h-إندازول-3-يل)?ينيل)-1h-بيرازول-1-يل)إيثانول بلوري
AU2012313885A1 (en) * 2011-09-30 2014-03-13 Pfizer Inc. Pharmaceutical compositions of N-methyl-2-[3-((E)-2-pyridin-2-yl-vinyl)-1H-indazol-6-ylsulfanyl]-benzamide
BR112014011453A2 (pt) 2011-11-11 2017-05-02 Pfizer n-metil-2-[3-((e)-2-piridin-2-il-vinil)-1h-indazol-6-ilsulfanil]-benzamida para o tratamento de leucemia mielógena crônica
AU2013208324B2 (en) 2012-01-13 2017-11-23 Xspray Microparticles Ab A pharmaceutical composition comprising stable, amorphous hybrid nanoparticles of at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component
US10098859B2 (en) 2012-09-05 2018-10-16 Amri Ssci, Llc Cocrystals of p-coumaric acid
EP2792360A1 (en) 2013-04-18 2014-10-22 IP Gesellschaft für Management mbH (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV
CN104230886A (zh) * 2013-06-24 2014-12-24 南京华威医药科技开发有限公司 阿昔替尼新晶型
WO2015067224A1 (en) 2013-11-08 2015-05-14 Zentiva, K.S. Salts of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-e-[2-(pyridin-2-yl)ethanyl] indazole
CN104650034A (zh) * 2013-11-22 2015-05-27 天津市汉康医药生物技术有限公司 一种稳定的阿西替尼化合物
EP3498734B1 (en) 2014-02-04 2021-09-01 Pfizer Inc. Combination of a pd-1 antagonist and a vegfr inhibitor for treating cancer
RU2667486C2 (ru) * 2014-03-31 2018-09-20 Сэндзю Фармацевтикал Ко., Лтд. Производное алкинилиндазола и его применение
CA2955676A1 (en) 2014-08-25 2016-03-03 Pfizer Inc. Combination of a pd-1 antagonist and an alk inhibitor for treating cancer
RU2714233C2 (ru) 2015-02-26 2020-02-13 Мерк Патент Гмбх Ингибиторы pd-1 / pd-l1 для лечения рака
WO2016178150A1 (en) * 2015-05-05 2016-11-10 Shilpa Medicare Limited Novel polymorphs of axitinib
KR20240034866A (ko) 2015-06-06 2024-03-14 클라우드브레이크 테라퓨틱스, 엘엘씨 익상편을 치료하기 위한 조성물 및 방법
AU2016280003B2 (en) 2015-06-16 2021-09-16 Merck Patent Gmbh PD-L1 antagonist combination treatments
CA3025049A1 (en) * 2016-05-16 2017-11-23 Pulmagen Therapeutics (Asthma) Limited Crystal of quinoline derivative
WO2017210132A1 (en) 2016-06-02 2017-12-07 Cloudbreak Therapeutics, Llc Compositions and methods of using nintedanib for treating ocular diseases with abnormal neovascularization
MX2019003755A (es) 2016-10-06 2019-08-12 Pfizer Regimen de dosificacion de avelumab para el tratamiento de cancer.
CN106883212A (zh) * 2017-03-16 2017-06-23 合肥拓锐生物科技有限公司 一种xli晶型阿昔替尼的制备方法
US20220370606A1 (en) 2018-12-21 2022-11-24 Pfizer Inc. Combination Treatments Of Cancer Comprising A TLR Agonist
US12290601B2 (en) 2019-05-09 2025-05-06 Synthon B.V. Pharmaceutical composition comprising axitinib
CN111187253B (zh) * 2020-01-09 2023-05-09 鲁南制药集团股份有限公司 一种阿昔替尼新晶型
CA3171563A1 (en) 2020-03-25 2021-09-30 Charles D. Blizzard Ocular implant containing a tyrosine kinase inhibitor
WO2022000265A1 (zh) * 2020-06-30 2022-01-06 天津理工大学 一种阿西替尼与戊二酸共晶及其制备方法
CN113943271B (zh) * 2020-07-15 2023-11-14 鲁南制药集团股份有限公司 一种阿昔替尼晶型及其制备方法
CN113943270B (zh) * 2020-07-15 2023-05-09 鲁南制药集团股份有限公司 一种阿昔替尼晶型
CN115531352B (zh) 2020-09-14 2025-04-25 视点制药公司 可生物蚀解的眼部药物递送插入剂及治疗方法
CN114685437B (zh) * 2020-12-25 2022-12-09 鲁南制药集团股份有限公司 阿昔替尼与糖精共晶
CN114685436B (zh) * 2020-12-25 2022-12-02 鲁南制药集团股份有限公司 阿昔替尼糖精共晶水合物
CN114685431B (zh) * 2020-12-26 2022-11-29 鲁南制药集团股份有限公司 一种阿昔替尼柠檬酸盐晶型
CN114685432B (zh) * 2020-12-28 2022-11-25 鲁南制药集团股份有限公司 阿昔替尼盐晶型及其制备方法
CN114685435B (zh) * 2020-12-28 2023-01-31 鲁南制药集团股份有限公司 阿昔替尼马来酸盐晶型及其制备
CN114685433B (zh) * 2020-12-28 2022-11-25 鲁南制药集团股份有限公司 一种阿昔替尼香草酸共晶盐及其制备
CN114685434B (zh) * 2020-12-28 2023-06-16 鲁南制药集团股份有限公司 一种阿昔替尼与戊二酸共晶
IL315262A (en) 2022-03-03 2024-10-01 Pfizer Multiple specific antibodies related to IL-4, IL-13 and/or TSLP and their uses
EP4282415A1 (en) 2022-05-26 2023-11-29 Genepharm S.A. A stable tablet composition of axitinib
TW202448436A (zh) 2023-04-11 2024-12-16 美商視爾普斯眼科公司 含有酪胺酸激酶抑制劑之眼部植入物
KR20250108329A (ko) 2024-01-08 2025-07-15 (주)유케이케미팜 엑시티닙의 제조방법
WO2025157389A1 (en) 2024-01-22 2025-07-31 Iomx Therapeutics Ag Combinations of halogenated heterocyclic kinase inhibitors and vegfr inhibitors
KR20250150872A (ko) 2024-04-12 2025-10-21 주식회사 스카이테라퓨틱스 액시티닙의 신규 분자 회합체

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20010306A1 (es) * 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
US7141581B2 (en) 1999-07-02 2006-11-28 Agouron Pharmaceuticals, Inc. Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
AU2930501A (en) † 2000-01-07 2001-07-24 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
US6627646B2 (en) * 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
CA2520932A1 (en) 2003-04-03 2004-10-14 Pfizer Inc. Dosage forms comprising ag013736
RU2007114112A (ru) 2004-11-02 2008-12-10 Пфайзер Инк. (US) Способ получения индазольных соединений
MX2007005291A (es) * 2004-11-02 2007-07-19 Pfizer Metodos para preparar compuestos de indazol.
WO2006048746A2 (en) 2004-11-02 2006-05-11 Pfizer Inc. Methods for the removal of heavy metals
KR20070060145A (ko) * 2004-11-02 2007-06-12 화이자 인코포레이티드 6-[2-(메틸카바모일)페닐설파닐]-3-ｅ-[2-(피리딘-2-일)에테닐]인다졸의 다형체 형태
CN101052633A (zh) 2004-11-02 2007-10-10 辉瑞大药厂 制备吲唑化合物的方法
US20080274192A1 (en) 2005-05-19 2008-11-06 Pfizer Inc. Pharmaceutical Compositions Comprising an Amorphous Form of a Vegf-R-Inhibitor
PT2134702T (pt) 2007-04-05 2017-07-31 Pfizer Prod Inc Formas cristalinas de 6-[2-(metilcarbamoil)fenilsulfanil]-3-e-[2-(piridin-2-il)etenil]indazol adequadas para o tratamento de crescimento celular anormal em mamíferos
AU2012313885A1 (en) † 2011-09-30 2014-03-13 Pfizer Inc. Pharmaceutical compositions of N-methyl-2-[3-((E)-2-pyridin-2-yl-vinyl)-1H-indazol-6-ylsulfanyl]-benzamide

Also Published As

Publication number Publication date
DK2134702T4 (da) 2023-09-25
WO2008122858A3 (en) 2009-05-07
EP2134702B2 (en) 2023-08-30
BRPI0809471A2 (pt) 2014-09-09
WO2008122858A9 (en) 2009-06-18
EP2134702A2 (en) 2009-12-23
US8791140B2 (en) 2014-07-29
CY1119119T1 (el) 2018-02-14
CA2682859A1 (en) 2008-10-16
CN103626739B (zh) 2015-12-30
EP4249063A2 (en) 2023-09-27
SG156088A1 (en) 2009-11-26
IL201320A (en) 2016-05-31
ES2919351T3 (es) 2022-07-26
TWI481602B (zh) 2015-04-21
ES2634866T5 (es) 2024-03-04
HK1193405A1 (zh) 2014-09-19
TW200911781A (en) 2009-03-16
SI2134702T1 (sl) 2017-07-31
SI2134702T2 (sl) 2023-12-29
AR065931A1 (es) 2009-07-08
PL2134702T5 (pl) 2023-12-04
CN101679356A (zh) 2010-03-24
KR101237588B1 (ko) 2013-02-27
PT2134702T (pt) 2017-07-31
RU2518898C2 (ru) 2014-06-10
EP3252047B1 (en) 2022-05-11
IL201320A0 (en) 2010-05-31
JP5869197B2 (ja) 2016-02-24
ES2634866T3 (es) 2017-09-29
DK2134702T3 (en) 2017-08-21
EP4249063A3 (en) 2024-03-13
EP3252047A2 (en) 2017-12-06
NZ580126A (en) 2012-03-30
PL2134702T3 (pl) 2017-10-31
EP3252047A3 (en) 2018-08-15
JP2009019030A (ja) 2009-01-29
RU2009136593A (ru) 2011-04-10
EP2134702B1 (en) 2017-05-31
JP2014193900A (ja) 2014-10-09
CA2682859C (en) 2013-10-08
AU2008236444A1 (en) 2008-10-16
WO2008122858A2 (en) 2008-10-16
WO2008122858A8 (en) 2009-11-26
CN103626739A (zh) 2014-03-12
AU2008236444B2 (en) 2012-06-28
US20100179329A1 (en) 2010-07-15
EP4074702A1 (en) 2022-10-19
FI2134702T4 (fi) 2023-09-12
KR20090127949A (ko) 2009-12-14

Similar Documents

Publication Publication Date Title
MX2009010761A (es) Formas cristalinas de 6-[2-(metilcarbamoil)fenilsulfanil]-3-e-[2-( piridin-2-il)etenil]indzol adecuadas para el tratamiento del crecimiento celular anormal en mamiferos.
WO2010002956A3 (en) Heterocyclic derivatives as modulators of ion channels
CA2818187C (en) Bromodomain inhibitors and uses thereof
NZ592897A (en) Crystals of laquinimod sodium, and process for the manufacture thereof
NO20076447L (no) Bicykliske derivater som modulatorer av ionekanaler
WO2007075895A3 (en) Heterocyclic derivatives as modulators of ion channels
WO2014028597A3 (en) 3-CYCLOHEXENYL AND CYCLOHEXYL SUBSTITUTED INDOLE AND INDAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
WO2007146284A3 (en) Thienopyrimidines useful as modulators of ion channels
WO2013184876A8 (en) Benzo [c] isoxazoloazepine bromodomain inhibitors and uses thereof
WO2014028600A3 (en) 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
AU2008321142A8 (en) Heterocyclic derivatives as modulators of ion channels
MX2010003009A (es) Piridil sulfonamidas como moduladores de canales ionicos.
PE20211756A1 (es) FORMAS POLIMORFICAS NOVEDOSAS DE UN INHIBIDOR DE TGFß
WO2008035380A3 (en) An improved process for the preparation of high purity formoterol and its pharmaceutically acceptable salts
AR081389A1 (es) Sal de tipo hemifumarato, composicion farmaceutica y proceso de obtencion de la misma.
WO2007126840A3 (en) Production of gossypol co-crystals
WO2010006904A3 (en) Crystalline forms of rabeprazole sodium
WO2007058989A3 (en) Quinazolines useful as modulators of voltage gated ion channels
BR112013018688A2 (pt) processo para a produção de composição polimérica de proantocianidina
CL2008002060A1 (es) Compuestos derivados de sulfonamida, inhibidores de la produccion de beta amiloide; metodo de preparacion; composicion farmaceutica; kit farmaceutico; y uso en el tratamiento de enfermedades tales como alzheimer, angiopatia amiloide, sindrome de down, entre otras.
CY1122140T1 (el) Μεθοδος παραγωγης φαρμακολογικως καθαρων κρυσταλλων
WO2010135505A3 (en) Crystalline forms of 4-[6-(6-methanesulfonyl-2-methylpyridin-3-ylamino)-5-methoxy-pyrimidin-4-yloxy]-piperidine-1-carboxylic acid isopropyl ester
MX2010008707A (es) Composiciones farmaceuticas de entacapona comicronizada con alcoholes de azucar.
MX354688B (es) Formas sólidas de (1r,4r)-6´-fluoro-(n,n-dimetil)-4-fenil-4´,9´-di hidro-3´h-espiro-[ciclohexano-1,1´-pirano-[3,4,b]indol]-4-amina y ácido sulfúrico.
CL2009001005A1 (es) Compuestos derivados de butirato de trimetilamonio, inhibidores de cpt2; proceso de preparacion; composicion farmaceutica que los comprende; y uso en el tratamiento o prevencion de enfermedades tales como hiperglucemia, diabetes, hipertension, entre otras patologias.

Legal Events

Date Code Title Description
FG Grant or registration